Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

1.

Titanium dioxide nanoparticle impact and translocation through ex vivo, in vivo and in vitro gut epithelia.

Brun E, Barreau F, Veronesi G, Fayard B, Sorieul S, Chanéac C, Carapito C, Rabilloud T, Mabondzo A, Herlin-Boime N, Carrière M.

Part Fibre Toxicol. 2014 Mar 25;11:13. doi: 10.1186/1743-8977-11-13.

2.

Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency.

Trotier-Faurion A, Passirani C, Béjaud J, Dézard S, Valayannopoulos V, Taran F, de Lonlay P, Benoit JP, Mabondzo A.

Nanomedicine (Lond). 2015 Jan;10(2):185-91. doi: 10.2217/nnm.13.205. Epub 2014 Feb 21.

PMID:
24559037
3.

Exposure to vehicle emissions results in altered blood brain barrier permeability and expression of matrix metalloproteinases and tight junction proteins in mice.

Oppenheim HA, Lucero J, Guyot AC, Herbert LM, McDonald JD, Mabondzo A, Lund AK.

Part Fibre Toxicol. 2013 Dec 17;10:62. doi: 10.1186/1743-8977-10-62.

4.

Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.

Trotier-Faurion A, Dézard S, Taran F, Valayannopoulos V, de Lonlay P, Mabondzo A.

J Med Chem. 2013 Jun 27;56(12):5173-81. doi: 10.1021/jm400545n. Epub 2013 Jun 7.

PMID:
23697594
5.
6.
7.

In vitro evidence of dysregulation of blood-brain barrier function after acute and repeated/long-term exposure to TiO(2) nanoparticles.

Brun E, Carrière M, Mabondzo A.

Biomaterials. 2012 Jan;33(3):886-96. doi: 10.1016/j.biomaterials.2011.10.025. Epub 2011 Oct 24.

PMID:
22027597
8.

In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery.

Lacombe O, Videau O, Chevillon D, Guyot AC, Contreras C, Blondel S, Nicolas L, Ghettas A, Bénech H, Thevenot E, Pruvost A, Bolze S, Krzaczkowski L, Prévost C, Mabondzo A.

Mol Pharm. 2011 Jun 6;8(3):651-63. doi: 10.1021/mp1004614. Epub 2011 Apr 15.

PMID:
21438632
9.

Drug bioanalysis and biomarker discovery at the Commissariat à l'énergie atomique et aux énergies alternatives.

Ezan E, Becher F, Benech H, Fenaille F, Junot C, Mabondzo A, Pruvost A.

Bioanalysis. 2010 Apr;2(4):713-7. doi: 10.4155/bio.10.16. No abstract available.

10.

Validation of in vitro cell-based human blood-brain barrier model using clinical positron emission tomography radioligands to predict in vivo human brain penetration.

Mabondzo A, Bottlaender M, Guyot AC, Tsaouin K, Deverre JR, Balimane PV.

Mol Pharm. 2010 Oct 4;7(5):1805-15. doi: 10.1021/mp1002366. Epub 2010 Sep 15.

PMID:
20795735
11.

In vivo effects of zearalenone on the expression of proteins involved in the detoxification of rat xenobiotics.

Duca RC, Mabondzo A, Bravin F, Delaforge M.

Environ Toxicol. 2012 Feb;27(2):98-108. doi: 10.1002/tox.20617. Epub 2010 Jul 6.

PMID:
20607812
12.

ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective.

Tsaioun K, Bottlaender M, Mabondzo A; Alzheimer's Drug Discovery Foundation.

BMC Neurol. 2009 Jun 12;9 Suppl 1:S1. doi: 10.1186/1471-2377-9-S1-S1. Review.

13.

Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A.

Antimicrob Agents Chemother. 2009 Mar;53(3):896-902. doi: 10.1128/AAC.00733-08. Epub 2008 Dec 15.

14.

Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.

Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, Farinotti R, Mabondzo A.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1147-54. doi: 10.1089/aid.2007.0022.

PMID:
18729774
15.

Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein.

Bousquet L, Pruvost A, Didier N, Farinotti R, Mabondzo A.

Eur J Pharm Sci. 2008 Nov 15;35(4):247-56. doi: 10.1016/j.ejps.2008.06.017. Epub 2008 Jul 18.

PMID:
18692133
16.

Endothelial cell-derived bone morphogenetic proteins control proliferation of neural stem/progenitor cells.

Mathieu C, Sii-Felice K, Fouchet P, Etienne O, Haton C, Mabondzo A, Boussin FD, Mouthon MA.

Mol Cell Neurosci. 2008 Aug;38(4):569-77. doi: 10.1016/j.mcn.2008.05.005. Epub 2008 May 20.

PMID:
18583149
17.

Endothelin-1 reduces p-glycoprotein transport activity in an in vitro model of human adult blood-brain barrier.

Hembury A, Mabondzo A.

Cell Mol Neurobiol. 2008 Nov;28(7):915-21. doi: 10.1007/s10571-008-9277-y. Epub 2008 Apr 1.

PMID:
18379872
18.

Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier.

Josserand V, Pélerin H, de Bruin B, Jego B, Kuhnast B, Hinnen F, Ducongé F, Boisgard R, Beuvon F, Chassoux F, Daumas-Duport C, Ezan E, Dollé F, Mabondzo A, Tavitian B.

J Pharmacol Exp Ther. 2006 Jan;316(1):79-86. Epub 2005 Oct 6.

19.

Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women.

Camus M, Deloménie C, Didier N, Faye A, Gil S, Dauge MC, Mabondzo A, Farinotti R.

Placenta. 2006 Jun-Jul;27(6-7):699-706. Epub 2005 Sep 12.

PMID:
16165208
20.

First Dominique Dormont International Conference on "Host-pathogen interactions in chronic infections - viral and host determinants of HCV, HCMV, and HIV infections".

Menu E, Müller-Trutwin MC, Pancino G, Saez-Cirion A, Bain C, Inchauspé G, Gras GS, Mabondzo AM, Samri A, Boutboul F, Le Grand R.

Retrovirology. 2005 Apr 6;2:24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk